Lakefront Biotherapeutics (LKFT) Capital Leases (2013 - 2017)

Lakefront Biotherapeutics (LKFT) has reported Capital Leases for 4 consecutive years, with $10596.9 the latest figure, recorded in Q4 2017.

• In Q4 2017, Capital Leases rose 9.05% year-over-year to $10596.9; the TTM figure through Dec 2017 stood at $10596.9 (up 9.05% YoY), while the FY2017 annual figure was $10596.9, up 6.36% from the prior year.
• Capital Leases declined to $10596.9 in Q4 2017 per LKFT's latest filing, from $40683.3 in the prior quarter.
• Across five years, Capital Leases topped out at $143730.9 in Q4 2014 and bottomed at $9717.5 in Q4 2016.
• Historically, Capital Leases has averaged $52694.2 across 4 years, with a median of $41805.4 in 2016.
• Annual changes were most pronounced in 2016 — Capital Leases tumbled 85.93% — and 2017, when it grew 9.05%.
• Lakefront Biotherapeutics' Capital Leases stood at $143730.9 in 2014, then sank by 51.96% to $69055.4 in 2015, then sank by 85.93% to $9717.5 in 2016, then gained by 9.05% to $10596.9 in 2017.
• Business Quant data shows LKFT's Capital Leases at $10596.9 in Q4 2017, $40683.3 in Q2 2017, and $53270.3 in Q1 2017.